935669-28-6

Basic information

• Product Name: 3-METHYLAZETIDINE HYDROCHLORIDE
• Synonyms: 3-METHYLAZETIDINE HYDROCHLORIDE;3-METHYLAZETIDINE BENZENESULFONATE;3-METHYLAZETIDINE BENZENESULFONIC ACID SALT;3-Methylazetidine hydroch...;3-Methylazetidine;METHYLAZETIDINE HYDROCHLORIDE;3-Methylazetidine HCl;Azetidine, 3-methyl-, hydrochloride
• CAS NO: 935669-28-6
• Molecular Formula: C₄H₉N*ClH
• Molecular Weight: 107.58
• Mol File: 935669-28-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-METHYLAZETIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYLAZETIDINE HYDROCHLORIDE(935669-28-6)
• EPA Substance Registry System: 3-METHYLAZETIDINE HYDROCHLORIDE(935669-28-6)

Safety Data

• Hazardous Substances Data: 935669-28-6(Hazardous Substances Data)

Usage

General Description

3-Methyiazetidine hydrochloride is a chemical compound that is an azetidine derivative. It is a white crystalline powder that is soluble in water. 3-METHYLAZETIDINE HYDROCHLORIDE is commonly used as a reagent in organic synthesis, particularly in the formation of chiral building blocks. It has been studied for its potential applications in pharmaceuticals, particularly in the development of new drugs. 3-Methyiazetidine hydrochloride has also been investigated for its antimicrobial and antifungal properties, showing potential as a new agent for the treatment of infections. Overall, it is a versatile chemical that has a wide range of potential applications in various fields.

InChI:InChI=1S/C4H9N.ClH/c1-4-2-5-3-4;/h4-5H,2-3H2,1H3;1H

Upstream product

• 934664-23-0 benzyl 3-methyleneazetidine-1-carboxylate 
• 35197-04-7 3-methyl-1-tosylazetidine 
• 40569-55-9 1-benzhydryl-3-methylene-azetidine 

Downstream Products

• 1418112-84-1 benzyl 3-methylazetidin-1-ylsulfonylcarbamate 
• 1611475-71-8 5-((benzyloxy)methyl)-2-butyl-7-(5-(3-methylazetidin-1-yl)pent-1-yn-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine 

Relevant articles and documents

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

Novel acetylcholine and carbamoylcholine analogues: Development of a functionally selective α4β2 nicotinic acetylcholine receptor agonist

A series of carbamoylcholine and acetylcholine analogues were synthesized and characterized pharmacologically at neuronal nicotinic acetylcholine receptors (nAChRs). Several of the compounds displayed low nanomolar binding affinities to the α4β2 nAChR and pronounced selectivity for this subtype over α3β4, α4β4, and α7 nAChRs. The high nAChR activity of carbamoylcholine analogue 5d was found to reside in its R-enantiomer, a characteristic most likely true for all other compounds in the series. Interestingly, the pronounced α4β2 selectivities exhibited by some of the compounds in the binding assays translated into functional selectivity. Compound 5a was a fairly potent partial α4β2 nAChR agonist with negligible activities at the α3β4 and α7 subtypes, thus being one of the few truly functionally selective α4β 2 nAChR agonists published to date. Ligand-protein docking experiments using homology models of the amino-terminal domains of α4β2 and α3β4 nAChRs identified residues Val111(β2)/Ile113(β4) , Phe119(β2)/Gln121(β4), and Thr155(α4)/Ser150(α3) as possible key determinants of the α4β2/α 3β4-selectivity displayed by the analogues.